Work

Abstract 6812: The third-generation FLT-3 inhibitor, PLM-102, is a promising therapeutic option for venetoclax-resistant AML

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-6812

Authors: Yun Sun Lee, Min Ji Park, Bongki Ko, Soo Jin Kim, Miran Moon, Soo Yeon Jang, Yong-Chul Kim

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409633562

Cites:

Cited by:

Related to: 10